Dalton Greiner Hartman Maher & Co. acquired a new position in shares of Invacare Co. (NYSE:IVC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 123,661 shares of the health services provider’s stock, valued at approximately $2,152,000. Dalton Greiner Hartman Maher & Co. owned about 0.31% of Invacare as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Invacare by 32.5% during the first quarter. Royal Bank of Canada now owns 1,155,919 shares of the health services provider’s stock worth $20,113,000 after purchasing an additional 283,846 shares during the period. Harvey Partners LLC increased its holdings in shares of Invacare by 3.9% during the first quarter. Harvey Partners LLC now owns 132,000 shares of the health services provider’s stock worth $2,297,000 after purchasing an additional 5,000 shares during the period. Millennium Management LLC increased its holdings in shares of Invacare by 318.5% during the first quarter. Millennium Management LLC now owns 1,455,746 shares of the health services provider’s stock worth $25,330,000 after purchasing an additional 1,107,858 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Invacare during the first quarter worth approximately $7,489,000. Finally, Barclays PLC increased its holdings in shares of Invacare by 76.4% during the first quarter. Barclays PLC now owns 58,338 shares of the health services provider’s stock worth $1,015,000 after purchasing an additional 25,273 shares during the period.
In other Invacare news, Director C Martin Harris sold 2,582 shares of the firm’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $16.38, for a total value of $42,293.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Baiju R. Shah sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $19.65, for a total transaction of $78,600.00. The disclosure for this sale can be found here. Insiders sold 26,582 shares of company stock worth $512,693 over the last three months. 2.10% of the stock is currently owned by insiders.
Shares of Invacare opened at $19.35 on Thursday, MarketBeat.com reports. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.10 and a quick ratio of 1.48. Invacare Co. has a 1 year low of $12.10 and a 1 year high of $20.00.
Invacare (NYSE:IVC) last announced its quarterly earnings data on Monday, May 7th. The health services provider reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. The business had revenue of $237.06 million for the quarter, compared to analysts’ expectations of $234.08 million. Invacare had a negative net margin of 7.60% and a negative return on equity of 13.88%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.47) earnings per share. equities research analysts anticipate that Invacare Co. will post -1.02 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 20th. Investors of record on Friday, July 6th will be paid a $0.0125 dividend. The ex-dividend date is Thursday, July 5th. This represents a $0.05 dividend on an annualized basis and a yield of 0.26%. Invacare’s dividend payout ratio (DPR) is -2.59%.
Several research analysts have recently commented on the stock. ValuEngine raised shares of Invacare from a “buy” rating to a “strong-buy” rating in a report on Friday, June 8th. UBS Group raised shares of Invacare from a “sell” rating to a “neutral” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Invacare from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, May 12th. Finally, KeyCorp lowered their target price on shares of Invacare from $24.00 to $23.00 and set an “overweight” rating on the stock in a report on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $21.50.
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through four segments: North America/Home Medical Equipment, Institutional Products Group, Europe, and the Asia/Pacific.
Want to see what other hedge funds are holding IVC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invacare Co. (NYSE:IVC).
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.